12/24
01:30 pm
mygn
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
Neutral
Report
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
12/24
06:18 am
mygn
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]
Medium
Report
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]
12/20
09:22 am
mygn
MYGN Stock Might Gain From the New Recognition of RiskScore Study [Yahoo! Finance]
Low
Report
MYGN Stock Might Gain From the New Recognition of RiskScore Study [Yahoo! Finance]
12/19
04:32 pm
mygn
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics [Yahoo! Finance]
Low
Report
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics [Yahoo! Finance]
12/19
04:15 pm
mygn
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Low
Report
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
12/17
07:32 am
mygn
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? [Yahoo! Finance]
Low
Report
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? [Yahoo! Finance]
12/13
11:16 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an "underperform" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an "underperform" rating on the stock.
12/10
06:26 pm
mygn
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Medium
Report
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
12/10
04:11 pm
mygn
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member [Yahoo! Finance]
Medium
Report
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member [Yahoo! Finance]
12/10
04:05 pm
mygn
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Medium
Report
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
12/10
08:14 am
mygn
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines [Yahoo! Finance]
Low
Report
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines [Yahoo! Finance]
12/10
08:00 am
mygn
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Low
Report
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
12/10
07:30 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
12/10
07:01 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $18.00 price target on the stock.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $18.00 price target on the stock.
12/9
04:15 pm
mygn
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium [Yahoo! Finance]
Medium
Report
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/9
04:05 pm
mygn
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Medium
Report
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
12/9
08:04 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $21.00 price target on the stock, down previously from $30.00.
Medium
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $21.00 price target on the stock, down previously from $30.00.
12/9
08:00 am
mygn
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
Low
Report
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
12/4
01:07 pm
mygn
Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO [Yahoo! Finance]
Low
Report
Franklin Biolabs Names Dr. Vatsala Naageshwaran as CEO [Yahoo! Finance]
11/29
09:29 am
mygn
New breast cancer combo sees success in New York trial [Yahoo! Finance]
Low
Report
New breast cancer combo sees success in New York trial [Yahoo! Finance]
11/25
08:37 am
mygn
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 [Yahoo! Finance]
Medium
Report
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 [Yahoo! Finance]
11/20
04:34 pm
mygn
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 [Yahoo! Finance]
Low
Report
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 [Yahoo! Finance]
11/20
04:30 pm
mygn
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Low
Report
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
11/20
03:11 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/19
08:20 am
mygn
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy [Yahoo! Finance]
Low
Report
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy [Yahoo! Finance]